Integrating anti-EGFR therapies in metastatic colorectal cancer

摘要: Colorectal cancer remains one of the most common causes diagnoses and mortality in United States. The treatment metastatic colorectal has evolved significantly over last decade with near-tripling patient survival rate. A significant contribution to this outcome was advent novel targeted agents, such as epidermal growth factor (EGFR) inhibitors. In an era emphasis on refining therapy, presence KRAS mutation will predict for resistance limit exposure patients who are more likely benefit. contrast, BRAF mutations does not seem have a predictive value. Agents that thought reverse EGFR inhibitors those targeting PI3K, c-MET or IGF-1R currently under study. EGFR exhibited single agent activity, synergize very well standard chemotherapy except cetuximab 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX). Preliminary data suggests similar effectiveness vascular endothelial (VEGF) first line setting. Skin toxicity main limiting utilization inhibitors, but strategies including use agents minocycline doxycycline added topical care severity rash.